chufangao/CTO huggingface dataset:
Clinical trial NCT05165771: Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 on Background Therapy With Conventional Synthetic Disease-modifying Antirheumatic Drug(s) (csDMARDs) in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decision to withdraw study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-07-31
Primary completion date: 2023-02-28
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT02304367: Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Official title: A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia
Sponsor: Kyowa Kirin Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-03-24
Primary completion date: 2017-07-27
Completion date: 2021-01-21
Baseline population: All enrolled participants
Clinical trial NCT03818321: Urinary Track Infection Prevention After Urogynecological Surgery
Official title: Methenamine Hippurate With Cranberry Capsules Versus Cranberry Capsules Alone for UTI Prevention in a Short-term Indwelling Foley Catheter Population After Urogynecological Surgery: A Double-Blinded Randomized Controlled Trial
Sponsor: TriHealth Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 185.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-17
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Clinical trial NCT04244877: Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
Official title: Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients
Sponsor: MetroHealth Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study was unable to recruit participants..
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-15
Primary completion date: 2023-05-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT04355039: INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Official title: A Phase I Study of INCB053914 (Pan-PIM Kinase Inhibitor) and Pomalidomide With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Terminated for lack of funding.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-01
Primary completion date: 2023-07-01
Completion date: 2024-07-01
Plan to share individual participant data: NO
Clinical trial NCT02602210: Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis
Official title: Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis
Acronym: SCOTCH;
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: low inclusion rate
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-01-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT03345784: Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
Official title: A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate accrual rate
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-29
Primary completion date: 2022-05-10
Completion date: 2022-05-10
Limitations and caveats: The main limitation of our study is the small number of patients enrolled due to premature closure; yet the study showed the limiting toxicities of this triplet combination.
Clinical trial NCT03849508: Phenylephrine Versus Norepinephrine for Maintenance of Hemodynamic During Cesarean Section Under Spinal Anesthesia
Official title: Randomized, Double-blind, Controlled Clinical Trial for Comparison of Continuous Phenylephrine Versus Norepinephrine Infusion for Maintenance of Hemodynamic Stability During Cesarean Section Under Spinal Anesthesia
Acronym: PHENAD
Sponsor: Centre Hospitalier Régional d'Orléans (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 124.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-27
Primary completion date: 2020-12-02
Completion date: 2020-12-02
Plan to share individual participant data: NO
Clinical trial NCT03131219: Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Official title: A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-31
Primary completion date: 2022-12-20
Completion date: 2022-12-20
Baseline population: Safety: All participants who received at least 1 dose of study drug.
Clinical trial NCT02268175: Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Official title: A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 75.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-31
Primary completion date: 2018-01-31
Completion date: 2021-12-31
Clinical trial NCT00981058: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Official title: A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Acronym: SQUIRE
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1093.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-01-07
Primary completion date: 2013-06-17
Completion date: 2024-05-30
Clinical trial NCT03419559: Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
Official title: A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combination With Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Iovance Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The treatment landscape for NSCLC has evolved in the past year. An additional NSCLC arm will be added to the IOV-COM-202 study using TIL + pembrolizumab.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-28
Primary completion date: 2021-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03620747: Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Official title: Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 393.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-30
Primary completion date: 2022-02-18
Completion date: 2022-02-18
Baseline population: Analysis was performed on all enrolled participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04978298: Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants
Official title: A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Effect of Ozanimod on Pressor Response to Oral Tyramine in Healthy Adult Subjects
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 128.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-07-19
Primary completion date: 2023-02-26
Completion date: 2023-02-26
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD time frame: See Plan Description
IPD access criteria: See Plan Description
Clinical trial NCT03694353: Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
Official title: An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria
Sponsor: BioMarin Pharmaceutical (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-13
Primary completion date: 2021-01-13
Completion date: 2021-01-13
Clinical trial NCT04413617: TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Official title: A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600 (RITLECITINIB) AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 460.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-07-29
Primary completion date: 2022-02-07
Completion date: 2022-02-07
Baseline population: Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04475302: BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots
Official title: Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India
Sponsor: Tuberculosis Research Centre, India (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 2175.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-01
Primary completion date: 2021-09-20
Completion date: 2021-09-20
Plan to share individual participant data: NO
Clinical trial NCT03530124: Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
Official title: A Prospective, Randomized, Open-label Clinical Trial to Assess Apnea Following Administration of 13-valent Conjugate Pneumococcal Vaccine, Diphtheria Toxoid, Tetanus Toxoid, and Acellular Pertussis Vaccine, Inactivated Polio Vaccine, Hepatitis B Vaccine, and Haemophilus Influenzae Type B Vaccine in Preterm Infants
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 223.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-17
Primary completion date: 2021-11-01
Completion date: 2021-11-01
Plan to share individual participant data: NO
Clinical trial NCT04154189: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Official title: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosarcoma (OLIE)
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 81.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-23
Primary completion date: 2022-06-22
Completion date: 2023-08-17
Baseline population: Full Analysis Set (FAS) included all randomized participants regardless of the treatment actually received.
Plan to share individual participant data: YES
IPD sharing description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Clinical trial NCT03848832: Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Official title: A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Acronym: ARCH
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated due to enrollment challenges and the COVID-19 pandemic.
Enrollment: 29.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-07-29
Primary completion date: 2021-01-21
Completion date: 2021-01-21
Baseline population: One participant assigned to the 5 mg/kg/Day placebo group was misdosed with 5 mg/kg/Day GWP42003-P. The participant was included in the 5 mg/kg/Day placebo group in the Intent-to-Treat Set but was included in the 5 mg/kg/day GWP42003-P group in the Safety Analysis Set (for which Baseline data are reported).
Limitations and caveats: This study was terminated early due to enrollment challenges and the Coronavirus disease-2019 (COVID-19) pandemic. Numbers of participants in each treatment groups were small, which precluded the planned formal statistical inferences and limited data interpretation.
Plan to share individual participant data: NO
Clinical trial NCT02834793: Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
Official title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 101.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-13
Primary completion date: 2021-05-26
Completion date: 2021-07-19
Baseline population: The safety analysis set (SAS) was the group of participants who received at least one dose of study drug and had at least one post-dose safety assessment.
Limitations and caveats: Study was terminated early by sponsor due to recruitment challenge, further impacted by COVID19, resulting in reduced sample size and variability in treatment response. Population PK analysis and PK/PD modeling planned for this study were not conducted and hence data was not collected and analyzed.
Clinical trial NCT04784520: A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
Official title: A Multicentre, Open-label, Single-arm Phase II Study of HA121-28 Tablets in Advanced Biliary Tract Cancer (BTC)
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The primary endpoint did not meet expectation.
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-22
Primary completion date: 2022-12-28
Completion date: 2022-12-28
Plan to share individual participant data: NO
Clinical trial NCT02481674: A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Official title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab
Acronym: SIGNAL-HD
Sponsor: Vaccinex Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 301.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Clinical trial NCT04631211: Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Official title: A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Sponsor: Cellphire Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated due to loss of funding for this indication from the Biomedical Advanced Research and Development Authority (BARDA) in November 2022.
Enrollment: 21.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-05
Primary completion date: 2022-01-07
Completion date: 2022-01-07
Plan to share individual participant data: NO
Clinical trial NCT04273737: Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy
Official title: Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: PI left institution.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-28
Primary completion date: 2022-02-22
Completion date: 2022-02-22
Baseline population: All participants who were enrolled.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04406857: Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
Official title: A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate accrual rate
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-17
Primary completion date: 2023-01-18
Completion date: 2023-01-18
Limitations and caveats: Trial had inadequate accrual rate
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Clinical trial NCT04490096: Multimodal Imaging Outcome Measures for ALS (Image ALS)
Official title: Multimodal Imaging Outcome Measures for ALS (Image ALS)
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Funding issues.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-25
Primary completion date: 2022-03-17
Completion date: 2022-03-17
Plan to share individual participant data: NO
Clinical trial NCT04421027: A Study of Baricitinib (LY3009104) in Participants With COVID-19
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Acronym: COV-BARRIER
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1525.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-12
Primary completion date: 2021-02-12
Completion date: 2021-06-10
Baseline population: All participants randomly assigned to study intervention. Participants were analyzed according to the intervention to which they were assigned.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting
IPD access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting
Clinical trial NCT01397968: Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Official title: A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Sponsor: SK Life Science, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 222.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-07-06
Primary completion date: 2013-06-30
Completion date: 2021-01-28
Clinical trial NCT03440385: Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Official title: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 606.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-07
Primary completion date: 2023-11-21
Completion date: 2023-11-21
Clinical trial NCT02835079: Treatment Effect of Tamoxifen on Patients With DMD
Official title: Treatment Effect of Tamoxifen on Patients With DMD
Sponsor: Hadassah Medical Organization (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 19.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-30
Primary completion date: 2020-11-30
Completion date: 2020-11-30